Piramal Pharma launches in-vitro biology capabilities at Ahmedabad discovery services site
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
Prateek has more than 23 years of rich experience in Human Resource
The new gummy capabilities include a dedicated R&D lab, an automated production line, and bottle packaging solutions
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
This product is bioequivalent to the reference listed drug (RLD), Nexium 24 HR Delayed- Release Capsules, 2.0mg (OTC), of AstraZeneca Pharmaceuticals
The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg
The sale/transfer of the Company's API NonAntibiotic Business and API Antibiotic Business to Apitoria are complete
Subscribe To Our Newsletter & Stay Updated